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Case Report

Recurrent breast cancer diagnosis delayed by
COVID-19 pandemic ✩,✩✩
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Article history:

We describe the case of a 65-year-old female with a history of left-sided ductal carcinoma in
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situ in 2008. Mammography in January 2020 demonstrated calcifications in the previously
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affected breast. Subsequent stereotactic biopsy results were benign. In the months that fol-
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lowed, the patient experienced breast changes but avoided returning to the facility as the
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COVID-19 pandemic worsened. In August of 2020, the patient returned for a repeat mammogram, which indicated 2 suspicious masses in the left breast. Further analysis through
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ultrasound-guided core biopsy ultimately led to a left mastectomy and lymph node biopsy,

Ductal carcinoma in situ (DCIS)

which were performed in September 2020. Pathology results revealed multifocal invasive

Invasive ductal carcinoma (IDC)

ductal carcinoma stage IIB.

COVID-19
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Case report
A 65-year-old female presented in January 2020 for routine
screening mammography. She had a history of ductal carcinoma in situ (DCIS) of the left breast in 2008, treated with
lumpectomy, radiation, and a 4-year course of Tamoxifen. The
Tamoxifen treatment was intended to reduce the risk of recurrence, however it was halted prematurely due to the patient’s
intolerance of the side effects. Medical records state that her
DCIS was estrogen receptor-positive (ER+) and progesterone
receptor-negative (PR-). The grade is unknown; however, the
inclusion of radiation in her treatment plan indicates it was
likely high-grade. After her initial diagnosis, the patient un-

✩

derwent annual mammography, which showed longitudinal
stability of postoperative changes and tissue density. No additional relevant medical history was noted. Since the patient is
adopted, no family history is available.
Her mammogram revealed new coarse heterogeneous calcifications 7 cm from the nipple in the inferomedial quadrant
of the left breast (Fig. 1A-B). The postlumpectomy changes of
the breast were stable at this time. These findings were assessed as BI-RADS category 4B: Moderate suspicion for malignancy. Supplemental screening ultrasound was not offered,
as it is not available at the facility and is not required in the
state. A stereotactic biopsy was performed later that month
and indicated proliferative fibrocystic changes, fibroadenomatoid hyperplasia, and benign calcifications. The patient was
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Fig. 1 – A-B: CC and MLO diagnostic mammography views
from January 2020 demonstrate coarse heterogeneous
calcifications in the lower inner quadrant, 7 cm from the
nipple (arrow). BIRADS 4B – stereotactic core biopsy
recommended.

scheduled to return for a repeat mammogram in 6 months
based upon the benign pathology result.
In May 2020, the patient noticed shrinking and hardening
of the left breast. Concerned about the ongoing COVID-19 pandemic, the patient chose not to return to the medical facility
for reevaluation and instead attributed these breast changes
to complications stemming from the stereotactic biopsy performed in January.
The patient returned in August 2020 for a 6-month followup mammogram which demonstrated new architectural
distortion measuring 15 mm in diameter, at 1:00 in the superomedial quadrant of the left breast 4 cm from the nipple
(Fig. 2A-B), distant from the site of the biopsy performed in
January. A breast ultrasound indicated an irregular, shadowing
mass with angular and spiculated margins (3.1 × 1.1 × 3 cm)
correlating to the area of architectural distortion identified
by mammography (Fig. 3A-B). This scan also demonstrated
an additional 1.5 × 1.5 × 0.9 cm oval, irregular mass with
angular margins in the same breast quadrant, at 3:00 3 cm
from the nipple (Fig. 4). The 3 axillary lymph nodes identified
on ultrasound had a benign appearance.
An ultrasound-guided core biopsy was performed on the
2 masses identified. Both masses were interpreted as invasive ductal carcinoma (IDC) grade 2. Immunohistochemistry
revealed that both tumors were ER+ 95%, PR-, and HER 2

Fig. 2 – A-B: Follow-up CC and MLO diagnostic
mammography views from August 2020 revealed a 15 mm
area of architectural distortion at 1:00 4 cm from the nipple
(star). Additionally, the area of architectural distortion is
much denser as compared to the similar area on the
January 2020 exam. Finally, the breast has decreased in
size relative to the prior exam.

oncogene-negative (Her2-). As the larger mass fell between 20
and 50 mm, the primary tumor was classified as T2.
The patient underwent a left mastectomy with biopsies of
4 sentinel lymph nodes in September 2020. In the absence
of symptoms of advanced metastasis (Mo), more comprehensive imaging studies were not performed in congruence with
the guidelines of the National Comprehensive Cancer Clinic
[1]. Micrometastasis was observed in 1 of the 4 lymph nodes
(N1mi). Biopsy pathology and the biomarker results confirmed
a diagnosis of multifocal IDC stage IIB (pT2mN1miMo). Adjuvant chemotherapy was initiated (TC—docetaxel with cyclophosphamide). An aromatase inhibitor was also prescribed
for adjuvant endocrine therapy.

Discussion
DCIS occurs when malignant epithelial cells spread within
the mammary ducts. Proliferation beyond the ducts results in
IDC. While the incidence of DCIS increased with the advent
of screening to make up 32.5 per 100,000 women in 2004, IDC
maintained a higher incidence of 124.3 per 100,000 women [2].
One-in-ten women treated for DCIS will later develop recurrent DCIS or IDC in the same breast, as occurred in the patient
profiled in this case study [3]. DCIS grade can predict future
IDC. In 2 cohorts of DCIS patients, the low-grade group had a
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Fig 4 – Also in August 2020, an additional oval, irregular
mass with angular margins (star) was noted at 3:00 3 cm
from the nipple measuring 1.5 × 0.9 × 0.9 cm. This was
also given a BI-RADS 5 assessment and ultrasound-guided
core biopsy was performed.

Fig. 3 – A-B: Radial and antiradial ultrasound images in
August 2020 demonstrate an irregular, shadowing mass
(star) with angular and subtle, spiculated margins at 1:00 4
cm from the nipple measuring 3.1 × 1.1 × 3.3 cm. This
correlated with the mammographic finding, was given a
BI-RADS 5 assessment, and ultimately underwent
ultrasound-guided core biopsy.

12-year invasive local recurrence rate of 7.5% while the highgrade group had a rate of 13.4% [4].
While DCIS and IDC may be first detected by screening,
IDC may also present with appreciable breast changes. These
include thickened, dimpled, or reddened breast skin, nipple
discharge or pain, and palpable lumps in the breast or axilla
[5]. Multifocal IDC is traditionally defined as separate tumors
within a breast quadrant, while multicentric IDC typically
refers to tumors separated by normal tissue and unconfined
to a single quadrant. As many studies do not distinguish
between the 2, the incidence of multifocal IDC appears to
range from 6% to 60% [6].
Following imaging, biomarker analysis, and biopsy pathology, surgical removal of the IDC tissue may proceed. In multifocal IDC, the noncancerous tissue from the affected breast
has a higher likelihood of being able to be conserved [7]. Docetaxel and cyclophosphamide (TC) are the standard adjuvant therapy for early-stage, HER- IDC [8]. Patients additionally
prescribed aromatase inhibitors have demonstrated approximately 40% lower breast cancer 10-year mortality rates than
those not treated with endocrine therapy [9].
After a state of emergency was declared in the United
States in March of 2020, many outpatient health care facilities closed to divert resources to the COVID-19 crisis. Individuals postponed elective screening due to concerns about the
virus. Screening mammography rates dropped by as much as

94% [10]. Initially, COVID-19 infection was suspected to impact
cancer patients more severely. As the pandemic has continued, international studies such as the COVID-19 and Cancer
Consortium have demonstrated that cancer patients and individuals without cancer share a similar risk of complications
or death from COVID-19. This was true regardless of cancer
type, treatment type, and treatment timing [11].
This patient’s case illustrates that those with increased
risk of breast cancer or those who are symptomatic should
not delay further evaluation, as disease can progress relatively
quickly. In this instance, the patient’s findings of a hardened,
shrinking breast were a cause for concern for the development of an underlying malignancy. Unfortunately, these
findings were misinterpreted as a complication of the recent
benign biopsy. This case also highlights the rapidity with
which breast malignancy may manifest. The initial benign
biopsy was for calcifications in a distant area of the breast
from which the cancer became evident within 6 months.
Despite the pandemic, patients with worrisome self-reported
physical exam findings should seek clinical evaluation by a
healthcare provider.

Patient consent
Written, informed consent was obtained from the patient featured in this case report.
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